Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cilgavimab (AZD-1061) is a humanized monoclonal antibody targeting the spike protein of SARS-CoV-2, used in studies of COVID-19 infection.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $645 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,530 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Cilgavimab (AZD-1061) is a humanized monoclonal antibody targeting the spike protein of SARS-CoV-2, used in studies of COVID-19 infection. |
In vitro | Cilgavimab has strong monoclonal antibody neutralization activity and human ACE2 blocking activity with IC50 of 10-150 ng/mL. Cilgavimab can bind to trimer S2Pecto protein or monomer SRBD protein with IC50 of 0.1-10 ng/mL. [1] |
In vivo | In a mouse model of SARS-CoV-2 infection, Cilgavimab (200 μg/ dose) treatment reduced the expression of inflammatory cytokine and chemokine genes in the lungs of the mice, reducing viral burden and lung inflammation levels. [1] |
Alias | COV2-2130, COV22130, AZD5156, AZD-1061, AZD1061, AZD 5156 |
Cas No. | 2420563-99-9 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.